A61P 37/02
Immunomodulators
A61P37/02 (Immunomodulators) appears on 36,931 US grants and 57,694 published applications in this corpus.
Search patents in A61P- Granted patents
- 36,931
- Published applications
- 57,694
- Assignees
- 12,379
- Inventors
- 75,644
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 5 | 0 |
| 1978 | 6 | 0 |
| 1979 | 15 | 0 |
| 1980 | 25 | 0 |
| 1981 | 11 | 0 |
| 1982 | 15 | 0 |
| 1983 | 26 | 0 |
| 1984 | 20 | 0 |
| 1985 | 19 | 0 |
| 1986 | 18 | 0 |
| 1987 | 37 | 0 |
| 1988 | 33 | 0 |
| 1989 | 39 | 0 |
| 1990 | 52 | 0 |
| 1991 | 63 | 0 |
| 1992 | 58 | 0 |
| 1993 | 81 | 0 |
| 1994 | 77 | 0 |
| 1995 | 101 | 0 |
| 1996 | 181 | 0 |
| 1997 | 229 | 0 |
| 1998 | 377 | 0 |
| 1999 | 550 | 0 |
| 2000 | 540 | 0 |
| 2001 | 655 | 163 |
| 2002 | 705 | 1035 |
| 2003 | 699 | 1703 |
| 2004 | 555 | 2021 |
| 2005 | 596 | 2054 |
| 2006 | 799 | 2113 |
| 2007 | 866 | 2160 |
| 2008 | 978 | 2424 |
| 2009 | 1239 | 2942 |
| 2010 | 1616 | 3537 |
| 2011 | 1802 | 3659 |
| 2012 | 2032 | 3542 |
| 2013 | 2256 | 2674 |
| 2014 | 2302 | 2743 |
| 2015 | 2052 | 2622 |
| 2016 | 1943 | 2703 |
| 2017 | 2077 | 2621 |
| 2018 | 1883 | 2355 |
| 2019 | 1834 | 2500 |
| 2020 | 1696 | 2014 |
| 2021 | 1396 | 1958 |
| 2022 | 1120 | 1873 |
| 2023 | 936 | 1766 |
| 2024 | 933 | 1840 |
| 2025 | 888 | 1510 |
| 2026 | 493 | 1162 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Cannabidiol nanodrug formulations and methods for use of the same6 Oct 2026US 12,751,959 B2University of Miami
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Composition for preventing or treating inflammatory bowel disease6 Oct 2026US 12,751,979 B2Ajou University Industry-Academic Cooperation Foundation
- Lipid nanoparticles comprising sterols and mRNA6 Oct 2026US 12,751,999 B2eTheRNA Immunitherapies NV
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Methods of treating diseases and disorders associated with foxp3 expression8 Oct 2026US 2026/0306482 A1Northwestern University
- Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase8 Oct 2026US 2026/0306487 A1Genentech, Inc.
- Mitochondrial uncouplers for treatment of metabolic diseases and cancer8 Oct 2026US 2026/0306502 A1Mito Biopharma, LLC
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Enhancer of number of tcr clones8 Oct 2026US 2026/0306562 A1Kabushiki Kaisha Yakult Honsha
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Drug releasing anastomosis devices and methods for treating anastomotic sites1,779US 7,108,701 B2Ethicon, Inc. · 2006
- Drug releasing biodegradable fiber implant1,662US 6,596,296 B1Board of Regents, The University of Texas System · 2003